EFTA01197764Set 9
8p3,954w
Pharma in 3O13
AIN -TTRO2 - TTRArnyloidosis (Alnylam) II = Phase III trial started in dQ13
ALN - VSP - Liver Cancer (Alnynam) Al Phase II testing in China in 2H13
AIN - PCS - High ... Enabled Therapeutics; There are currently three LNP-based products in clinical
development ALN-TTR02, ALN-VSP, and ALN-PCS02 targeting amyloidosis, liver cancer and high
cholesterol respectively. Anlylam ... Adults Relapsed Look* $1.24 $1.91 $3.46 $3.5S $3.64 $3.73 $3.82 $3.91 $4.01 $4.10
ALN •TTRO2 TTR Amyl
https://www.justice.gov/epstein/files/DataSet%209/EFTA01197764.pdf